Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques.

Autor:	Voutsinas N; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York nicholas.voutsinas@mountsinai.org., Lekperic S; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York., Barazani S; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York., Titano JJ; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York., Heiba SI; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York., Kim E; Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2018 Nov; Vol. 59 (11), pp. 1649-1654. Date of Electronic Publication: 2018 Aug 02.
DOI:	10.2967/jnumed.116.186346
Abstrakt:	90 Y radioembolization is an increasingly used treatment for both primary and metastatic malignancy in the liver. Understanding the biophysical properties, dosing concerns, and imaging appearance of this treatment is important for interventional radiologists and nuclear medicine physicians to provide important therapy. 90 Y radioembolization is efficacious and safe, although the possibility of complications does exist. This article provides a comprehensive in-depth discussion about the indications for 90 Y radioembolization, reviews the role of preprocedural angiography and 99m Tc-macroaggregated albumin scans, illustrates different dosing techniques, compares and contrasts resin and glass microspheres, and describes potential complications. (© 2018 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu